Cambridge Cognition Holdings (LON:COG), the software company that has developed a touch screen system to detect neuropsychological disorders, said trading for 2015 should match last year’s performance.
The firm said it had won contracts and upfront payments for clinical trial work worth around US$4.5mln.
It said it expects next year to be one of ‘material growth’.
Chief operating officer Steven Powell said: "We are pleased to have made significant progress in our pharmaceutical clinical trials business and these contracts provide a strong foundation for continued growth in 2016."